COVID-19 pandemic
A limited-size clinical trial in Johannesburg suggests that the Oxford–AstraZeneca COVID-19 vaccine is weak against the 501.V2 variant of SARS-CoV-2.
Sources: The Wall Street Journal
Changes
- A limited-size clinical trial in Johannesburg suggests the Oxford–AstraZeneca COVID-19 vaccine is weak against the 501.V2 variant of SARS-CoV-2.
- A limited-size clinical trial in Johannesburg suggests the Oxford–AstraZeneca COVID-19 vaccine is weak against the 501.V2 variant of SARS-CoV-2.
- A limited-size clinical trial in Johannesburg suggests that the Oxford–AstraZeneca COVID-19 vaccine is weak against the 501.V2 variant of SARS-CoV-2.